|
Market Closed -
Nasdaq
16:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 28.10 USD | +4.69% |
|
-6.52% | +22.12% |
| 08-10 | Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-05 | Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.66B | - | - | - | - | - |
| 46.05B | |||||
| 43.59B | - | - | - | - | - |
| 42.35B | |||||
| 38.86B | |||||
| 32.24B |
Select your edition
All financial news and data tailored to specific country editions
